Tim Freeman - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tim Freeman


Tim Freeman Pharmtech contributing editor and EAB member

Tim Freeman
Managing Director, Freeman Technology

tim.freeman@freemantech.co.uk

www.freemantech.co.uk

Tim Freeman is Managing Director of powder characterization company Freeman Technology for whom he has worked since the mid 1990s. He was instrumental in the original design and continuing development of the FT4 Powder Rheometer and in the past decade has co-led the team that has grown Freeman Technology from a start-up business to the global organization of today. Through his work with various professional bodies and involvement in industry initiatives Tim is an established contributor to wider developments in powder processing.

Tim has a degree in Mechatronics from the University of Sussex in the UK. He has extensive experience in application and method development for the FT4 Powder Rheometer and works closely with customers worldwide across the powder processing industries. Tim is a mentor on a number of project groups for the Engineering Research Center for Structured Organic Particulate Systems in the US. He is a frequent contributor to industry conferences, instructs on training courses for powder processing and writes regularly for a variety of publications.

In the pharmaceutical field Tim is a past Chair of the American Association of Pharmaceutical Scientists (AAPS) Process Analytical Technology Focus Group and is a member of the Editorial Advisory Boards of Life Science Leader magazine (Jameson Publishing Inc. http://www.lifescienceleader.com) and Pharmaceutical Technology (Advanstar Communications Inc. www.pharmtech.com)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here